Orexo reports positive results from phase I study for OX19
Many elderly people suffer from nocturia and in particular amongst women, incontinence is a common problem. Treatment with the peptide desmopressin is currently the most effective treatment for many of these patients.
Orexo’s ambition is to develop improved drug formulations of desmopressin for a more efficient treatment of nocturia and incontinence. Orexo has developed a new nasal spray formulation for the administration of desmopressin, and results from a recently completed phase I study confirm significantly better absorption for the new nasal spray formulation than for current nasal spray on the market.
In the clinical study, Orexo compared its new nasal powder spray with a current liquid nasal spray in 13 healthy volunteers.
The study showed that the uptake of desmopressin into the blood stream was three times higher than that of the current liquid nasal spray, with no delay in time to reach maximal plasma concentration. The drug concentrations in the blood showed lower variability compared to the reference product. Reduced variability is essential for a reproduceable effect. The study also showed excellent tolerance of both spray formulations and no unexpected adverse events.
The study also included a sublingual tablet formulation. However, the bioavailability of desmopressin did not increase enough to reach the primary objective for the sublingual tablet formula.
“We are pleased with the results of the study. Next step will be to seek a partner for the continued development of the nasal powder formulation of desmopressin.”, says Torbjörn Bjerke, President and CEO, Orexo AB.
For more information, please contact:
Torbjörn Bjerke, President and CEO, Orexo AB
Tel: +46 (0)708-66 19 90
Claes Wenthzel, Executive Vice President & CFO, Orexo AB
Tel: +46 (0)18-780 88 44